Is genetic testing required to use Platinib?

The use of platinib does require genetic testing. Platinib is a targeted drug targeting RET gene fusion mutations. Before use, confirming whether the patient has RET gene fusion through genetic testing is the key to determining whether the drug is suitable. Only by identifying this specific genetic mutation can doctors accurately develop treatment plans for patients.

Genetic testing can help identify the patient groups most suitable for platinib treatment. For those patients who do carry the RET fusion gene, platinib can show significant therapeutic effects, such as tumor shrinkage and symptom relief. This precision treatment strategy helps maximize the therapeutic effect of the drug.

For patients who do not carry theRET fusion gene, the use of platinib may not achieve the expected therapeutic effect, and may even cause unnecessary side effects and economic burden. Therefore, genetic testing can help prevent these patients from receiving inappropriate treatments.

The results of genetic testing can provide important reference information for doctors to help them make more informed decisions when formulating treatment plans. For example, platinib may be an effective treatment option for patients who have had poor response to other treatments, such as chemotherapy or immunotherapy, if genetic testing reveals the presence of a RET fusion gene.

According to domestic and foreign lung cancer treatment guidelines and consensus, multi-gene testing including the RET gene is recommended for patients with inoperable and advanced non-small cell lung cancer (NSCLC). As a targeted drug targeting the RET fusion gene, the use of platinib naturally needs to follow this norm.